Financial Data and Key Metrics Changes - The company finished the last quarter with approximately $550 million in cash, which is expected to be sufficient to reach profitability [57][58] - In the first full quarter of the Iptrozi launch, there were 204 new patient starts, significantly higher than the previous generation drug Repotrectinib, which had 34 patient starts in its first quarter [20][19] Business Line Data and Key Metrics Changes - Iptrozi (Taltrectinib) has shown a nearly 90% response rate and a progression-free survival (PFS) duration of over 50 months, which is unprecedented in the ROS1 non-small cell lung cancer space [3][8] - Safusidenib, a mutant IDH1 inhibitor for glioma, has demonstrated a 44% response rate in low-grade glioma with only 12% progression at two years, compared to Vorasidenib's 11% response rate and 41% progression [4][36] Market Data and Key Metrics Changes - The potential market for Iptrozi is estimated at over $5 billion annually, with an increase in new patient diagnoses expected due to more sensitive RNA testing methods [11][12] - The glioma market is split evenly between high-grade and low-grade, with Vorasidenib achieving $1 billion in sales in its first year despite only being approved for a subset of low-grade gliomas [43][35] Company Strategy and Development Direction - The company aims to expand its market presence by moving into the adjuvant setting for early-stage ROS1 lung cancer, which could increase market opportunities by approximately 30% [32][33] - The company is focused on developing Safusidenib for both high-grade and low-grade gliomas, targeting areas where existing treatments are lacking [37][38] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial potential of Iptrozi, citing its superior efficacy and tolerability compared to competitors, which positions it well for market share capture [10][13] - The management highlighted the importance of increasing awareness and testing for ROS1 mutations, which could lead to a broader patient base for their therapies [15][17] Other Important Information - The company has received 80% payer coverage for Iptrozi, which is expected to increase as the drug is recognized as a preferred therapy in NCCN guidelines [22][27] - The company is committed to its drug-drug conjugate program, which is currently being refined based on learnings from early clinical trials [52][55] Q&A Session Summary Question: What are the key drivers of early success for Iptrozi? - The early success is attributed to the drug's superior tolerability and efficacy compared to Repotrectinib, leading to significantly higher patient starts [20][19] Question: How does the reimbursement landscape look for Iptrozi? - The company expects coverage to increase due to the drug's clinical benefits and the younger demographic of ROS1 patients, making it hard to deny coverage [23][24] Question: What impact do NCCN guidelines have on market positioning? - The updated NCCN guidelines now contraindicate IO chemotherapy for ROS1 patients, favoring the use of ROS1 agents like Iptrozi, which is expected to enhance adoption [27][28] Question: What is the market opportunity for Safusidenib? - The glioma market is substantial, with potential revenue stacking for both low-grade and high-grade gliomas, especially if the drug demonstrates robust efficacy [44][46] Question: What are the timelines for regulatory strategy regarding Safusidenib? - The company plans to conduct a PFS study for Safusidenib, with results expected no later than 2029, while also exploring the possibility of revisiting response rate endpoints with the FDA [48][50]

Financial Data and Key Metrics Changes - The company is focused on achieving financial excellence, particularly improving EBITDA margins to align with or exceed competitors [5][6][11] - A three-year plan was announced, targeting a revenue growth rate of 5%-7% [13][15] - The company aims for a net leverage of 3.5 times by 2028 [18] Business Line Data and Key Metrics Changes - The Vision 27 program is designed to enhance operational efficiency and gross margins across various business lines [6][11] - The contact lens segment is expected to grow faster than the market, with a new bioactive platform, Project Halo, set to launch in 2028 [21][27] - The dry eye product portfolio, including Xiidra and Miebo, is positioned as the gold standard in the market [52] Market Data and Key Metrics Changes - The contact lens market has slowed to about 4% growth, influenced by economic conditions in Asia, particularly China [28][29] - The company anticipates a recovery in the contact lens market, projecting growth to return to 5% or higher by 2026 [29] Company Strategy and Development Direction - The company is committed to organic growth, with no M&A planned in the three-year strategy [18] - Focus on innovation is critical, with a deep pipeline of products expected to drive future growth [90] - The company aims to leverage its existing infrastructure for new product launches to maintain high margins [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation into a high-performance competitor, emphasizing the importance of innovation and operational excellence [5][6] - The management highlighted the need for a disciplined approach to spending as growth resumes [9][11] - The company is optimistic about the aging population's demand for premium IOLs, viewing it as a growth driver [89] Other Important Information - The company is focusing on enhancing its R&D efficiency, aiming to allocate more resources towards product development rather than administrative costs [50] - The introduction of new products like Lumify Luxe and the expansion of the PreserVision brand are seen as significant growth opportunities [44][46] Q&A Session Summary Question: How should investors think about the liquidity of Bausch + Lomb given its ownership structure? - Management acknowledged the 88% ownership by Bausch Health and indicated that both boards are committed to addressing liquidity issues, though the timeline is uncertain [12] Question: What are the components of the 5%-7% revenue long-range plan? - Management explained that the guidance is based on current market conditions and internal capabilities, with a balanced approach to growth [13][15] Question: How does the company view tuck-in M&A opportunities? - Management stated that no M&A is needed at this time, focusing instead on organic growth and improving the balance sheet [18] Question: What is the expected timeline for the new bioactive contact lens material? - The new product is expected to launch in 2028, with ongoing clinical studies providing positive data [24][27] Question: How does the company plan to manage its R&D budget? - The company is increasing its R&D spending to about 7.5% of revenue, focusing on high-potential programs [48][50] Question: What is the outlook for the dry eye market? - Management believes they have the best portfolio for dry eye treatment, with Xiidra and Miebo positioned as leading products [52] Question: What is the growth outlook for the surgical business? - The surgical business is expected to grow steadily, driven by an aging population and consistent demand for IOLs [89]

Financial Data and Key Metrics Changes - Vertex Pharmaceuticals reported nearly $500 million in revenue for the first nine months of the launch of vanzacaftor/tezacaftor/deutivacaftor, indicating a strong start for the product [20][21][22] - The company expects revenue for Casgevy to exceed $100 million in 2025, showing a steady ramp in patient infusions [79] Business Line Data and Key Metrics Changes - The launch of the acute pain product has seen over 300,000 prescriptions written, with a significant increase from 10,000 in Q1 to 190,000 in Q3 [7][21] - The company has achieved formulary placement in several large hospitals and healthcare systems, exceeding initial expectations [6] Market Data and Key Metrics Changes - Vertex has over 170 million covered lives in the US for its new pain product, with a goal of reaching approximately 300 million [5][6] - The company is making progress in discussions with payers, particularly on the Medicaid side, while still working on Medicare access [8][9] Company Strategy and Development Direction - Vertex is focusing on diabetic peripheral neuropathy (DPN) as a key area for development, with ongoing Phase 3 studies expected to complete enrollment in 2026 [12][19] - The company is exploring opportunities in B-cell mediated diseases, particularly through the POVI program, which targets IgA nephropathy and membranous nephropathy [52][54] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum of the acute pain product launch and the positive feedback from physicians and payers [6][7] - The company is optimistic about the potential of POVI and its differentiated profile in treating renal diseases, anticipating significant market opportunities [54][71] Other Important Information - Vertex is actively engaged in share buyback programs, having repurchased approximately $2 billion worth of shares this year [88] - The company is in late preclinical development for novel conditioning regimens to improve patient outcomes in gene therapies [82] Q&A Session Summary Question: What is the outlook for the new pain product? - Management highlighted the significant progress in prescriptions and payer access, indicating a strong trajectory for the product [5][6] Question: How is the company addressing the challenges in chronic pain? - The focus is on DPN due to its well-defined clinical path and the lack of high-quality treatments, with ongoing studies expected to yield positive results [12][19] Question: What are the expectations for Casgevy's market access? - The company reported strong access and reimbursement across major markets, with expectations for significant revenue growth in 2025 [85] Question: What is the strategy for future acquisitions or investments? - Vertex aims to maintain flexibility for internal and external investments, with a focus on high-quality science and potential new therapeutic areas [88]

Financial Data and Key Metrics Changes - The company reported strong Q1 results with all five operating segments showing double-digit profit growth, particularly in the pharma and specialty services business, which experienced significant profit growth driven by strong demand, execution, and focus on specialty services [4][5] - The guidance for fiscal year 2026 was raised to $9.65-$9.85, reflecting confidence in the business model and the ability to navigate regulatory changes [7][8] - The company is generating strong cash flow, raising adjusted free cash flow guidance to $3 billion-$3.5 billion for the year, and increasing CapEx guidance to $600 million-$650 million [56][58] Business Line Data and Key Metrics Changes - The pharma and specialty services business, which is the largest segment, saw outsized demand across its portfolio, contributing to strong growth [5][11] - The "Other" segment, which includes at-home nuclear precision health and OptiFreight, reported 60% profit growth, with each business growing more than the long-term target of 10% [5] - The GMPD business, part of the turnaround strategy, showed positive profit and cash flow, successfully navigating tariff impacts [54] Market Data and Key Metrics Changes - The company is experiencing strong demand in the generic market, with a robust pipeline of pharmaceuticals expected to go generic in the next five years, contributing to confidence in future growth [12][36] - The introduction of oral GLP-1s is anticipated to simplify distribution and potentially improve profitability, although the impact remains uncertain [29] - The biosimilars market is still in early stages, with the company focusing on supporting development while acknowledging hurdles to widespread adoption [41] Company Strategy and Development Direction - The company is focused on long-term investments and growth opportunities, managing the business with a multi-quarter outlook rather than short-term results [6][58] - The MSO strategy is differentiated by not being solely reliant on pharmaceutical revenue, instead leveraging strengths in various specialties and building an ecosystem that connects suppliers and clinical practices [20][24] - The company aims to maintain a strong balance sheet while returning capital to shareholders, with plans for M&A opportunities that align with existing strategies [59] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating regulatory changes and maintaining profitability despite potential pressures from WAC reductions [14][15] - The company is optimistic about the at-home solutions business, positioning itself as a strong partner for the administration's regulatory goals [49][50] - The GMPD business turnaround is progressing well, with management highlighting productive conversations with customers regarding pricing adjustments [54] Other Important Information - The company is investing in its nuclear business, with a $150 million investment in new capacity and a focus on theranostics, which is expected to drive growth [43][45] - The competitive bidding rules for the at-home solutions business are expected to have a small near-term financial impact, with significant time to adapt before they take effect [50] Q&A Session Summary Question: How does the company view the sustainability of profit growth? - Management noted that while the long-term growth target is 5%-7%, recent performance has exceeded expectations due to outsized demand and strong operational execution [10][11] Question: What is the impact of WAC reductions on the distribution business? - Management acknowledged concerns but emphasized that the company has been adapting to industry changes and expects to be compensated for the services provided, regardless of regulatory changes [14][15] Question: How is the MSO strategy differentiated from competitors? - The company highlighted its focus on strengths in various specialties and the integration of data and clinical practices, rather than solely relying on pharmaceutical revenue [20][24] Question: What are the expectations for the generics market? - Management indicated strong demand and a robust pipeline of generics, while maintaining a cautious outlook on long-term growth expectations of 2%-3% [36][37] Question: What is the outlook for biosimilars? - Management expressed aspirations for the biosimilars market but noted that it is still in early stages and not yet a significant contributor to profitability [41][42]

Financial Data and Key Metrics Changes - Total revenue for Q3 grew 9% year-over-year to $219.1 million, while subscription revenue increased 5% year-over-year to $190.3 million [4][16] - Non-GAAP operating income was $33.5 million, resulting in a 15% non-GAAP operating margin for the quarter [19][20] - Free cash flow generated in Q3 was $15.5 million, with a year-to-date total of $126 million [20] - Non-GAAP net income per diluted share was $0.12, with a projected range of $0.09 to $0.10 for Q4 [19][23] Business Line Data and Key Metrics Changes - Professional services revenue was $28.8 million, attributed to large CCaaS rollouts expected to translate into future subscription revenue [17] - Subscription revenue-based net dollar expansion rate was 102%, indicating stabilization [17][18] - The number of customers contributing $1 million or more in subscription revenue decreased by four to 145, but revenue from this cohort grew 9% year-over-year [18] Market Data and Key Metrics Changes - Total remaining performance obligations (RPO) were $857.6 million, down 5% year-over-year, while current RPO was $562.2 million, up 3% year-over-year [21] - Calculated billings for Q3 were $158.4 million, an increase of 7% year-over-year [21] Company Strategy and Development Direction - The company is focused on deepening engagement with its top 700 customers through Project Bear Hug, which aims to improve renewal rates and customer relationships [9][14] - The strategy includes leveraging AI-powered platforms for personalized customer engagement and enhancing operational efficiencies [5][6] - The company is in a transitional year, with plans to embed foundational changes into operations and culture for sustainable growth [8][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategy and noted that while challenges remain, there are signs of improvement in key metrics and customer engagement [8][14] - The leadership team changes are complete, and management is focused on maintaining productivity and driving growth [42][44] - The company expects Q4 revenue to be in the range of $216.5 million to $217.5 million, representing 7% growth year-over-year at the midpoint [22][24] Other Important Information - The company has a strong balance sheet with $480.3 million in cash and marketable securities and no debt [20] - The company is investing in AI and R&D talent to enhance customer service and go-to-market capabilities [23][24] Q&A Session Summary Question: How sustainable is the revenue performance as the company heads into next year? - Management indicated that while Q3 performance was strong, it is essential to string several quarters together to assess sustainability [30][31] Question: What is at risk with Project Bear Hug and what outcomes can be expected? - Management noted that the initiative aims to deepen customer relationships and has shown positive results, with some accounts seeing reduced downsell risks [33][36] Question: How is the leadership team stabilizing after recent changes? - Management stated that the major leadership changes are complete and emphasized the importance of having experienced team members to drive the transformation [42][44] Question: How did renewals in Q3 compare to expectations? - Management reported that renewal rates were better than expected, with improved predictability in forecasting [50][51] Question: What is the status of the pricing and bundling strategy? - Management confirmed that the first phase of the new pricing and bundling strategy has been implemented with positive early feedback [58][59] Question: What is the progress on large deployments like Deutsche Telekom? - Management indicated significant improvements in execution and positive feedback from customers during the rollout of large implementations [60][61] Question: What are the expectations for AI capabilities and investments? - Management highlighted that AI is fundamental to the platform and will continue to be a focus for investment, with over 300 AI skills already in place [64][66]

Financial Data and Key Metrics Changes - Total revenue for Q3 grew 9% year-over-year to $219.1 million, while subscription revenue increased 5% year-over-year to $190.3 million [5][16] - Non-GAAP operating income was $33.5 million, resulting in a 15% non-GAAP operating margin for the quarter [5][20] - Professional services revenue was $28.8 million, driven by large CCaaS rollouts, with a net dollar expansion rate of 102% [17][18] - Non-GAAP subscription gross margin was 77%, and total non-GAAP gross margin was 67% [19][20] Business Line Data and Key Metrics Changes - The company is focusing on Project Bear Hug, which aims to deepen engagement with the top 700 customers, representing over 80% of total revenue [9] - The revenue contributed by the $1 million customers' cohort increased by 9% year-over-year, with a net dollar expansion rate of 113% [18] Market Data and Key Metrics Changes - Total remaining performance obligations (RPO) were $857.6 million, down 5% year-over-year, while current RPO was $562.2 million, up 3% year-over-year [21] - The company expects total billings of approximately $320 million for Q4, traditionally the strongest quarter [22] Company Strategy and Development Direction - The company is in a transformation phase, focusing on improving its position in the customer experience market and leveraging its AI-powered platform [6][8] - The strategy includes enhancing customer engagement through first-party data and personalized omnichannel experiences [6][14] - The leadership team has been strengthened with new appointments, including a new CFO and Chief Product and Corporate Strategy Officer [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and commitment to driving sustainable growth and long-term shareholder value [8][14] - The company is optimistic about improving renewal rates and customer engagement metrics, indicating a stronger position than at the start of the year [8][14] - Management acknowledged that transformation takes time and emphasized the importance of executing several quarters together to establish a solid foundation [30][75] Other Important Information - The company generated $15.5 million in free cash flow in Q3 and $126 million year-to-date, with a strong balance sheet of $480.3 million in cash and no debt [20] - The company raised its full-year revenue guidance, now expecting total revenue in the range of $853 million to $854 million, representing 7% growth year-over-year [24] Q&A Session Summary Question: How sustainable is the revenue performance as the company heads into next year? - Management indicated that while Q3 showed good performance, it is essential to string several quarters together to assess sustainability [29][30] Question: What is at risk with Project Bear Hug, and what outcomes can be expected? - Management explained that Bear Hug aims to deepen customer relationships, and successful engagement can lead to better renewal rates and reduced churn [32][36] Question: How is the company stabilizing its leadership bench amid recent changes? - Management stated that most senior leadership changes are complete, and the current team is experienced and aligned with the company's strategy [40][42] Question: How did renewals in Q3 compare to expectations, and what is anticipated for Q4? - Management reported that renewal rates met or exceeded expectations in Q3, and they are actively managing renewals for upcoming quarters [49][50] Question: Can you provide an update on pricing and bundling initiatives? - Management confirmed that the first phase of new pricing and bundling has been implemented with positive early feedback, and plans to expand this to existing customers are underway [58][60]

Sprinklr (NYSE:CXM) Q3 2026 Earnings Call December 03, 2025 08:30 AM ET Speaker2Greetings. Welcome to the Sprinklr Third Quarter Fiscal Year 2026 Financial Results Call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. At this time, I'll turn the conference over to E ...

Financial Data and Key Metrics Changes - The company aims for an annual system sales growth of 8%+, supported by approximately 3% comparable sales growth and around 5% net unit growth over time [2] - The international business has shown strong performance, with 18 consecutive quarters of positive same-store sales [16][44] Business Line Data and Key Metrics Changes - Tim Hortons in Canada has been performing exceptionally well, being the number one brand in value for money and convenience, with about 4,000 restaurants [39] - Burger King in the U.S. has maintained consistent promotions like the $5 Duos and $7 Trios, contributing to its performance despite a challenging environment [12][30] Market Data and Key Metrics Changes - The Canadian consumer environment has been stable, with some improvement in consumer confidence and a slight decrease in unemployment [6] - The U.S. lower-income consumer segment has been softer, while middle and upper tiers have shown more strength [7][8] Company Strategy and Development Direction - The company is focused on simplifying its business model, aiming to be predominantly asset-light and franchised, with significant steps taken in refranchising and partnerships [25][26] - The partnership with CPE in China is seen as a strategic move to enhance growth and operational efficiency in that market [50][53] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the competitive pressure from food at home versus food away from home, emphasizing the importance of value for money [10][11] - The company is optimistic about returning to modestly positive unit growth in 2026, with a focus on untapped potential in various international markets [67] Other Important Information - An Investor Day is scheduled for February 26, 2024, to provide further insights into the company's strategy and performance [14] - The company has seen significant growth in its international markets, particularly in France, Germany, and Australia, with ongoing expansion in India and China [44][46][48] Q&A Session Summary Question: How do you describe the health of the consumer across different groups? - Management noted a mixed environment, with lower-income consumers being softer while middle and upper tiers remain strong [6][7] Question: What is the company's strategy regarding pricing in the current environment? - The company has been prudent about pricing, focusing on value for money across its brands [11][12] Question: What are the key drivers of success for the company in the current environment? - Key drivers include value for money positioning, innovation in product offerings, and operational improvements [29][30] Question: What are the expectations for unit growth in the coming years? - The company expects to return to 5% unit growth by 2028, with modestly positive growth anticipated in 2026 [57][66]

Financial Data and Key Metrics Changes - The company aims for annual system sales growth of over 8%, supported by approximately 3% same-store sales growth and around 5% net unit growth over time [2] - The Canadian business has shown strong performance despite a softer consumer environment, with recent improvements in consumer confidence and a slight decrease in unemployment [6][7] - The U.S. consumer segment, which constitutes about 30% of the business, has seen consistent dynamics, with lower-income consumers being softer while middle and upper tiers remain stable [8][9] Business Line Data and Key Metrics Changes - Tim Hortons in Canada is positioned as the number one brand in value for money, with a strong focus on everyday value rather than heavy discounting [29] - Burger King U.S. has maintained consistent promotions like $5 Duos and $7 Trios, focusing on the Whopper and family activations to drive traffic [12][32] - Firehouse Subs has achieved significant growth, opening 100 net new units in the last four quarters, marking a 3-4x increase in growth pace since acquisition [67] Market Data and Key Metrics Changes - The international business accounts for about 30% of operating income, with 18 consecutive quarters of positive same-store sales [44] - France is the largest international market, with several billion-dollar revenue businesses in countries like Germany, Australia, and Spain [45] - The company is expanding Popeyes into new markets, achieving strong results in places like the U.K. and China [46] Company Strategy and Development Direction - The company is focused on simplifying its business model, aiming to become predominantly asset-light and franchised, with significant refranchising efforts planned for 2026 [25][26] - The partnership with CPE in China is seen as a strategic move to enhance operations and growth potential, with a $350 million capital injection planned [50][53] - The company is optimistic about unit growth, targeting a return to 5% net unit growth by 2028, with a focus on markets like China and India [57][66] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges posed by the current consumer environment but remains confident in the company's value positioning and operational improvements [11][29] - The company is monitoring the potential impact of GLP-1 medications on consumer behavior, particularly in the U.S. market [21][22] - The focus for 2026 will be on executing the existing plan and continuing to simplify operations while driving growth in both domestic and international markets [24][66] Other Important Information - An Investor Day is scheduled for February 26, where management will address investor questions and provide further insights into the business [14] - The company has maintained a strong franchisee base in Canada, which is crucial for operational success and community engagement [39][40] Q&A Session Summary Question: How does the company view the health of the consumer across different groups? - Management noted a mixed environment, with lower-income consumers being softer while middle and upper tiers remain stable [6][8] Question: What is the company's strategy regarding pricing in the current environment? - The company emphasizes prudent pricing strategies across its brands, focusing on value for money to attract consumers [11][12] Question: What are the key drivers of success for the company's brands in a challenging environment? - Key drivers include value positioning, innovation in product offerings, and operational improvements [29][30] Question: How does the company view its international business? - Management highlighted the importance of international markets, noting consistent performance and significant growth potential [15][44] Question: What are the expectations for unit growth moving forward? - The company aims for modestly positive net unit growth in 2026, with a long-term target of 5% by 2028 [57][66]

Financial Data and Key Metrics Changes - The company aims for annual system sales growth of over 8%, supported by approximately 3% same-store sales growth and around 5% net unit growth over time [2] - The Canadian business has shown strong performance, with 18 consecutive quarters of positive same-store sales [16][41] - The U.S. consumer environment has been mixed, with lower-income consumers showing softness, while middle and upper tiers have remained stable [7] Business Line Data and Key Metrics Changes - Tim Hortons in Canada is positioned as the number one brand in value for money, with a focus on everyday value rather than heavy discounting [28] - Burger King U.S. has maintained consistent promotions like $5 Duos and $7 Trios, focusing on value and family-oriented marketing [11][30] - Popeyes has expanded significantly, with successful launches in markets like China and the U.K., achieving strong unit economics [43] Market Data and Key Metrics Changes - The international business accounts for about 30% of operating income, with significant growth in markets like France, Germany, and Australia [41] - The company has seen positive same-store sales across its international business for 18 consecutive quarters, indicating strong performance [41] - Emerging markets like India and China are viewed as having substantial growth potential, with ongoing expansion plans [45] Company Strategy and Development Direction - The company is focused on simplifying its business model, aiming for a predominantly asset-light and franchised structure [24][25] - The partnership with CPE in China is expected to enhance growth, with a significant capital injection of $350 million to support expansion [50] - The company plans to continue refranchising restaurants, with expectations to refranchise 50-100 restaurants in 2025 and increase that number in 2026 [25] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a mixed consumer environment but remains optimistic about the company's ability to navigate challenges through value positioning and operational improvements [10][28] - The company expects modestly positive net restaurant growth in China in 2026, following a year of store base cleanup [60] - There is confidence in achieving long-term unit growth targets of 5% by 2028, driven by strong performance in international markets and ongoing operational improvements [62] Other Important Information - An Investor Day is scheduled for February 26, 2026, to provide further insights into the company's strategy and performance [13] - The company emphasizes the importance of its non-U.S. businesses, which contribute significantly to overall operating income [14] Q&A Session Summary Question: How does the company view the health of the consumer across different groups? - The company notes a mixed environment, with lower-income consumers being softer, while middle and upper tiers remain stable [7] Question: What is the company's strategy to compete with food at home? - The company focuses on providing value for money and has been prudent with pricing across its brands [10][11] Question: What are the key drivers of success in the current environment? - Key drivers include value positioning, innovation in product offerings, and operational improvements [28][30] Question: What are the expectations for unit growth in the coming years? - The company expects to achieve modestly positive unit growth in 2026, with a long-term target of 5% by 2028 [62]